Anti-CD22-CAR-transduced T cells (Southwest Hospital)

Anti-CD22-CAR-transduced T cells is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Southwest Hospital in China. The therapy involves genetically modifying a patient's own T cells to express a CAR that specifically recognizes CD22, a cell surface antigen predominantly expressed on B-lineage cells. Once infused back into the patient, these engineered T cells target and eliminate CD22-positive malignant B cells. This therapy is primarily being investigated for the treatment of relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and various B-cell lymphomas, particularly in patients who have failed CD19-targeted therapies.

Other names

CD22-targeted CAR-T cellsCD-22-targeted CAR-T cellsCD 22-targeted CAR-T cellsCD22 CAR-TCD-22 CAR-TCD 22 CAR-T